Additionally, in vivo studies have demonstrated the efficacy of a recently developed monoclonal antibody anti-CSF-1R (RG7155) in the reduction of CD68+/CD163+ TAMs in mesothelioma biopsies [102]. The gene discussed is CSF1R; the disease is mesothelioma.